stock
CELU · Celularity Inc
Revenue $5.43M last quarter, down 5% on a year earlier; no insider buys or sales filed in 90 days; last 8-K filed Oct 29: other event.
Follow CELU freePrice
Loading the CELU chart…
Chart by TradingView
The business
What the company does and what it reports, from its SEC filings.
What it is
We are a cellular and regenerative medicine company focused on advancing health longevity and redefining the standard of care for age-related disease using novel therapies derived from the post-partum human placenta. The objective of extending health longevity is to meaningfully reduce the duration and severity in which an individual experiences aging-related degenerative diseases and disorders associated with increased mortality towards the end of life. Aging is known to be a major risk factor for many degenerative disorders and diseases across multiple high-value therapeutic areas, including immunology and regenerative medicine. Common to all degenerative disorders and diseases is the progressive loss of function or structure (or both) of affected tissues and organs driven by underlying cellular dysfunction.
From the 10-K for the fiscal year ended Dec 31, 2025, filed Apr 30, 2026.
Read the 10-K on SEC- Sector
- Life Sciences (SEC office)
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Employees
- 115
- Headquarters
- Florham Park, NJ
- Incorporated in
- DE
- Fiscal year ends
- December
- Exchange
- Nasdaq
- Fractional shares
- No
- Listed options
- Yes
- Filer category
- <br>Emerging growth company
- Formerly
- GX Acquisition Corp. (until 2021)
- Shares outstanding
- 32,450,679 as of Oct 19, 2026 (XBRL frame )
- Filer (SEC EDGAR)
- EDGAR filing index
Key stats
Valuation and the ratios that use the live price are free with an account.
Start free to see thisDeep value
- NCAV
- -$125.25M
- NCAV per share
- -$3.86
- NNWC
- -$127.24M
- NNWC per share
- -$3.92
Expectations
- Free cash flow
- —
- Free cash growth, last 5 years
- —
- Revenue growth, last 5 years
- 13.2%
Margins
- Gross
- —
- Operating
- -264.3%
- Net
- -245.7%
Returns
- ROE
- —
- ROA
- -47.7%
Health
- Current ratio
- 0.1x
- Debt/equity
- —
Trailing twelve months to Jun 30, 2026; balance sheet at Jun 30, 2026.
Debt is long-term debt and its current portion. Commercial paper and short-term borrowings are not counted.
Results
| Period end | Revenue | Gross profit | Operating income | Net income | Filing |
|---|---|---|---|---|---|
| Jun 30, 2026 | $5.43M | — | -$4.24M | $706,000 | |
| Mar 31, 2026 | $3.85M | — | -$10.13M | $874,000 | Assembled from more than one filing; the filing above is only the newest of them. |
| Dec 31, 2025 | $4.10M | — | -$22.06M | -$24.36M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| Sep 30, 2025 | $5.28M | — | -$12.90M | -$23.08M | |
| Jun 30, 2025 | $5.74M | — | -$15.86M | -$24.52M | |
| Mar 31, 2025 | $11.43M | — | -$10.49M | -$19.75M | Assembled from more than one filing; the filing above is only the newest of them. |
| Dec 31, 2024 | $18.13M | — | -$9.28M | -$13.29M | Derived: the full year minus the first three quarters, not a figure this filer reported as a quarter. |
| Sep 30, 2024 | $9.30M | — | -$11.53M | -$16.10M |
- Cash
- $586,000
- Debt
- —
- Net cash
- —
- Current assets
- $6.45M
- Current liabilities
- $59.74M
- Working capital
- -$53.29M
- Total liabilities
- $131.70M
- Assets
- $96.17M
- Equity
- -$35.53M
Balance as of Jun 30, 2026.
SEC data as of Nov 17, 2026
Earnings moves
No results filings
Ten years
| Fiscal year end | Revenue | Operating income | Net income | Free cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $26.55M | -$61.31M | -$91.72M | — |
| Dec 31, 2024 | $54.22M | -$38.36M | -$57.89M | -$6.56M |
| Dec 31, 2023 | $22.77M | -$192.29M | -$196.29M | -$39.73M |
| Dec 31, 2022 | $17.98M | -$25.60M | $14.19M | -$143.11M |
| Dec 31, 2021 | $21.34M | -$109.06M | -$100.12M | -$116.30M |
| Dec 31, 2020 | $14.28M | -$151.93M | -$208.23M | -$91.03M |
| Dec 31, 2019 | — | -$1.68M | $5.88M | — |
What it filed
Material events and 5% ownership filings from the last year.
Company filings
2 offering filings in 12 months
events
5% owners ()
PHILIP & DANIELE BARACH FAMILY TRUST
Stake update
PHILIP & DANIELE BARACH FAMILY TRUST
Stake update
PHILIP & DANIELE BARACH FAMILY TRUST
Stake update
PHILP & DANIELE BARACH FAMILY TRUST
Activist stake
Lincoln Alternative Strategies LLC
Stake update
Owners and trading
Insider, politician and fund moves, short interest, and the volume traded off the exchange.
Insiders, politicians and funds
Insider trades, last 90 days
No insider buys or sales filed in the last 90 days.
Politician trades, last 90 days
No politician trades filed in the last 90 days.
Funds
None of the tracked funds held this at their last 13F.
Short interest
Hard to borrow: Alpaca will not lend it for shorting
Shares short
534,811
Of shares outstanding
1.6%
Days to cover
2.3
Change since last report
+21.1%
Settlement date Oct 30, 2026
Off-exchange short volume, 20 days
57.6%
Through Nov 17, 2026
Of the volume reported to FINRA's off-exchange facilities, market makers' hedging included. It is not short interest.
Short interest and short volume: FINRA
Off-exchange and dark pools
About 55.2% of shares traded off the exchanges
Period ending Oct 30, 2026, FINRA
Week of Oct 12, 2026, published by FINRA 2 to 4 weeks later
- Dark pools (ATS)6.7%
- Wholesalers and other dealers93.3%
Venues, week of Oct 12, 2026
Top dark pools
- INCR INTELLIGENT CROSS LLC3,530
- CGXS ONECHRONOS1,633
- EBXL LEVEL ATS1,516
- IATS IBKR ATS945
- KCGM VIRTU MATCHIT ATS920
This shows where shares traded, not who bought or sold. Most off-exchange volume is retail orders filled by wholesalers.
Source: FINRA
Members see
- Signals: which strategies fired on CELU, and the evidence behind each
- Options positioning: the levels dealers are hedged around
- Technicals: trend and momentum readings
- Earnings moves: how the price moved after each report
- News: stories counted once across outlets
nakagai
Signals on CELU come from a rule, not a model.
Nakagai’s scanner records a signal the moment a strategy’s rule matches on the bars. Members read those signals on their own desk, where an agent journals the tape and briefs them in plain English.
Follow CELU free
Comments · 0
No comments yet.